http://www.ds-pharma.com/ir/library/presentation/pdf/eir20120229.pdf Slide 2 again mentions small sales force. 2015 earliest launch date.
You are out of your minds if you think 90% of you will still even be employed here by then. In addition, there is no way any of your will be selling Onc drugs. Not only do they tink so little of this saelsforce but they will want reps with established relationships (which are worth much more in Onc, MS, etc) and as well as general knowledge about the Onc disease state as it can be a somewhat difficult disease state to understand and sell in. If you are using this acquisition as part of your career panning you are going to be in big trouble in the near future.
So they are going to end up paying the same $2.6 billion that they did for Sepracor. Sepracor had 1700 sales reps at the time, profit generating products like Lunesta, Xopenex, Omnaris, Alvesco, and Brovana being marketed, and Stedesa in the wings. BB has 30 people all together, 2 molecules and no promoted products, and until 2015 will only consume more of DSP's cash. No wonder the investors tried to sue AA and the board to prevent the buyout by DSP. We were sold to them for a song.
IMO they significantly over paid for Sepracor and looks like they are doing the same for these two molecules. The R&D folks and their expertise who they are also purchasing can leave at any time which makes this purchase even more horrible. I bang my head against the wall and try to see how a successful company can pay that much for Sep and not see all of the issues that were here from me too products, bad sales force and managed care teams as well as pipeline and incompetent exec mgt.
Until DSP finally decides to act on the mess at Sunovion, clean house of all the incompetant senior leaders that have no business being in the positions they have, remove the internal barriers that exist so that products may achieve their potential, and do away with the "good old boy" network here that is so blatantly obvious, thier purchase of Sunovion was a waste of money. DSP should have commercialized their products on their own. Sunovion also has a completely inept business development group, complicating the problems here even further. Message to Tada: do something now or you will have little left of any value.
Yeah, and we have a pretty pathetic sales force, most of whom think they are way better than they really are who are really only good at one thing, casting blame on others.
Spoken by one of the managers who obviously was not smart enough to hire good people, and also likes to cast blame on others.
